M Potrony1,2, J A Puig-Butille2,3, M Ribera-Sola1, V Iyer3, C D Robles-Espinoza4,5, P Aguilera1,2, C Carrera1,2, J Malvehy1,2, C Badenas2,3, M T Landi6, D J Adams5, S Puig1,2. 1. Dermatology Department, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. 2. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain. 3. Biochemistry and Molecular Genetics Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. 4. Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Santiago de Querétaro, Mexico. 5. Experimental Cancer Genetics Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge, U.K. 6. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, U.S.A.
Abstract
BACKGROUND: Germline mutations in telomere-related genes such as POT1 and TERT predispose individuals to familial melanoma. OBJECTIVES: To evaluate the prevalence of germline mutations in POT1 and TERT in a large cohort of Spanish melanoma-prone families (at least two affected first- or second-degree relatives). METHODS: Overall, 228 CDKN2A wild-type melanoma-prone families were included in the study. Screening of POT1 was performed in one affected person from each family and TERT was sequenced in one affected patient from 202 families (26 families were excluded owing to DNA exhaustion/degradation). TERT promoter sequencing was extended to an additional 30 families with CDKN2A mutation and 70 patients with sporadic multiple primary melanoma (MPM) with a family history of other cancers. RESULTS: We identified four families with potentially pathogenic POT1 germline mutations: a missense variant c.233T>C (p.Ile78Thr); a nonsense variant c.1030G>T (p.Glu344*); and two other variants, c.255G>A (r.125_255del) and c.1792G>A (r.1791_1792insAGTA, p.Asp598Serfs*22), which we confirmed disrupted POT1 mRNA splicing. A TERT promoter variant of unknown significance (c.-125C>A) was detected in a patient with MPM, but no germline mutations were detected in TERT promoter in cases of familial melanoma. CONCLUSIONS: Overall, 1·7% of our CDKN2A/CDK4-wild type Spanish melanoma-prone families carry probably damaging mutations in POT1. The frequency of TERT promoter germline mutations in families with melanoma in our population is extremely rare.
BACKGROUND: Germline mutations in telomere-related genes such as POT1 and TERT predispose individuals to familial melanoma. OBJECTIVES: To evaluate the prevalence of germline mutations in POT1 and TERT in a large cohort of Spanish melanoma-prone families (at least two affected first- or second-degree relatives). METHODS: Overall, 228 CDKN2A wild-type melanoma-prone families were included in the study. Screening of POT1 was performed in one affected person from each family and TERT was sequenced in one affected patient from 202 families (26 families were excluded owing to DNA exhaustion/degradation). TERT promoter sequencing was extended to an additional 30 families with CDKN2A mutation and 70 patients with sporadic multiple primary melanoma (MPM) with a family history of other cancers. RESULTS: We identified four families with potentially pathogenic POT1 germline mutations: a missense variant c.233T>C (p.Ile78Thr); a nonsense variant c.1030G>T (p.Glu344*); and two other variants, c.255G>A (r.125_255del) and c.1792G>A (r.1791_1792insAGTA, p.Asp598Serfs*22), which we confirmed disrupted POT1 mRNA splicing. A TERT promoter variant of unknown significance (c.-125C>A) was detected in a patient with MPM, but no germline mutations were detected in TERT promoter in cases of familial melanoma. CONCLUSIONS: Overall, 1·7% of our CDKN2A/CDK4-wild type Spanish melanoma-prone families carry probably damaging mutations in POT1. The frequency of TERT promoter germline mutations in families with melanoma in our population is extremely rare.
Authors: Kim Wong; Carla Daniela Robles-Espinoza; David Rodriguez; Saskia S Rudat; Susana Puig; Miriam Potrony; Chi C Wong; James Hewinson; Paula Aguilera; Joan Anton Puig-Butille; Brigitte Bressac-de Paillerets; Hélène Zattara; Louise van der Weyden; Christopher D M Fletcher; Thomas Brenn; Mark J Arends; Víctor Quesada; Julia A Newton-Bishop; Carlos Lopez-Otin; D Timothy Bishop; Paul W Harms; Timothy M Johnson; Alison B Durham; David B Lombard; David J Adams Journal: JAMA Dermatol Date: 2019-05-01 Impact factor: 10.282
Authors: Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson Journal: J Med Genet Date: 2006-08-11 Impact factor: 6.318
Authors: Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao Journal: J Am Acad Dermatol Date: 2009-10 Impact factor: 11.527
Authors: Hans Vasen; Isaura Ibrahim; Carmen Guillen Ponce; Emily P Slater; Elvira Matthäi; Alfredo Carrato; Julie Earl; Kristin Robbers; Anneke M van Mil; Thomas Potjer; Bert A Bonsing; Wouter H de Vos Tot Nederveen Cappel; Wilma Bergman; Martin Wasser; Hans Morreau; Günter Klöppel; Christoph Schicker; Martin Steinkamp; Jens Figiel; Irene Esposito; Evelina Mocci; Enrique Vazquez-Sequeiros; Alfonso Sanjuanbenito; Maria Muñoz-Beltran; José Montans; Peter Langer; Volker Fendrich; Detlef K Bartsch Journal: J Clin Oncol Date: 2016-04-25 Impact factor: 44.544
Authors: Mary L McMaster; Chongkui Sun; Maria T Landi; Sharon A Savage; Melissa Rotunno; Xiaohong R Yang; Kristine Jones; Aurélie Vogt; Amy Hutchinson; Bin Zhu; Mingyi Wang; Belynda Hicks; Anand Thirunavukarason; Douglas R Stewart; Stella Koutros; Alisa M Goldstein; Stephen J Chanock; Neil E Caporaso; Margaret A Tucker; Lynn R Goldin; Yie Liu Journal: Br J Haematol Date: 2018-05 Impact factor: 6.998
Authors: Mark Harland; Mia Petljak; Carla Daniela Robles-Espinoza; Zhihao Ding; Nelleke A Gruis; Remco van Doorn; Karen A Pooley; Alison M Dunning; Lauren G Aoude; Karin A W Wadt; Anne-Marie Gerdes; Kevin M Brown; Nicholas K Hayward; Julia A Newton-Bishop; David J Adams; D Timothy Bishop Journal: Fam Cancer Date: 2016-01 Impact factor: 2.375
Authors: Oriol Calvete; Paula Martinez; Pablo Garcia-Pavia; Carlos Benitez-Buelga; Beatriz Paumard-Hernández; Victoria Fernandez; Fernando Dominguez; Clara Salas; Nuria Romero-Laorden; Jesus Garcia-Donas; Jaime Carrillo; Rosario Perona; Juan Carlos Triviño; Raquel Andrés; Juana María Cano; Bárbara Rivera; Luis Alonso-Pulpon; Fernando Setien; Manel Esteller; Sandra Rodriguez-Perales; Gaelle Bougeard; Tierry Frebourg; Miguel Urioste; Maria A Blasco; Javier Benítez Journal: Nat Commun Date: 2015-09-25 Impact factor: 17.694
Authors: Erica Shen; Joanne Xiu; Giselle Y Lopez; Rex Bentley; Ali Jalali; Amy B Heimberger; Matthew N Bainbridge; Melissa L Bondy; Kyle M Walsh Journal: J Med Genet Date: 2020-01-14 Impact factor: 6.318
Authors: María Sánchez-Ares; Soledad Cameselle-García; Ihab Abdulkader-Nallib; Gemma Rodríguez-Carnero; Carolina Beiras-Sarasquete; José Antonio Puñal-Rodríguez; José Manuel Cameselle-Teijeiro Journal: Front Endocrinol (Lausanne) Date: 2022-02-28 Impact factor: 5.555